Catalyst Wire Dossier Catalyst Wire Dossier

NRC-2694-A

· NATCO Pharma Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NRC-2694-A, covering 2026-01-23 to 2026-01-23. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy [Phase 2]

See pricing